In April, I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application (IND) to initiate clinical study for TJM2 to treat cytokine release syndrome (CRS) associated with severe illness caused by the coronavirus disease 2019 (COVID-19). The Company has also obtained central institutional review board (IRB) approval from the Western Institutional Review Board on the same day.
The webinar will focus on the challenges on the treatment of severe COVID-19 and the role cytokines play in the disease progression. It will also discuss the current status on the development of new compounds, especially GM-CSF antibodies.
